Clinical trials
Recruiting Multiple Sclerosis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
347 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 6 |
| 2017 | 8 |
| 2018 | 5 |
| 2019 | 9 |
| 2020 | 10 |
| 2021 | 17 |
| 2022 | 18 |
| 2023 | 46 |
| 2024 | 63 |
| 2025 | 88 |
| 2026 | 67 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 347 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 6 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 5 |
| Tongji Hospital | 5 |
| University Hospital, Basel, Switzerland | 5 |
| University of Illinois at Chicago | 5 |
| Assistance Publique - Hôpitaux de Paris | 4 |
| Brigham and Women's Hospital | 4 |
| Fondazione Don Carlo Gnocchi ETS | 4 |
| Heinrich-Heine University, Duesseldorf | 4 |
| Shirley Ryan AbilityLab | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Sclerosis | 347 |
| Multiple Sclerosis, Relapsing-Remitting | 30 |
| Parkinson Disease | 22 |
| Multiple Sclerosis, Chronic Progressive | 21 |
| Fatigue | 20 |
| Neuromyelitis Optica | 20 |
| Stroke | 20 |
| Autoimmune Diseases of the Nervous System | 13 |
| Myasthenia Gravis | 12 |
| Cognitive Dysfunction | 11 |
Trials
Showing 76 to 100 of 347. Each trial links to its page on Pharma Observatory.
247 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.